NRP1 inhibition modulates radiosensitivity of medulloblastoma by targeting cancer stem cells.
Fiche publication
Date publication
décembre 2022
Journal
Cancer cell international
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CHASTAGNER Pascal, Pr BOURA Cédric, Dr DAOUK Joël
Tous les auteurs :
Douyère M, Gong C, Richard M, Pellegrini-Moïse N, Daouk J, Pierson J, Chastagner P, Boura C
Lien Pubmed
Résumé
Medulloblastoma (MB) is the most common pediatric malignant brain tumor. Despite current therapies, the morbidity and recurrent risk remains significant. Neuropilin-1 receptor (NRP1) has been implicated in the tumor progression of MB. Our recent study showed that NRP1 inhibition stimulated MB stem cells differentiation. Consequently, we hypothesized that targeting NRP1 in medulloblastoma could improve current treatments.
Mots clés
Cancer stem cells, Medulloblastoma, Neuropilin-1, Radiotherapy
Référence
Cancer Cell Int. 2022 12 1;22(1):377